BR112022000231A2 - Novos métodos - Google Patents

Novos métodos

Info

Publication number
BR112022000231A2
BR112022000231A2 BR112022000231A BR112022000231A BR112022000231A2 BR 112022000231 A2 BR112022000231 A2 BR 112022000231A2 BR 112022000231 A BR112022000231 A BR 112022000231A BR 112022000231 A BR112022000231 A BR 112022000231A BR 112022000231 A2 BR112022000231 A2 BR 112022000231A2
Authority
BR
Brazil
Prior art keywords
new methods
methods
lumateperone
disorder
administering
Prior art date
Application number
BR112022000231A
Other languages
English (en)
Inventor
Kimberly Vanover
Robert Davis
Sharon Mates
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of BR112022000231A2 publication Critical patent/BR112022000231A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

novos métodos. a presente invenção refere-se a métodos para o tratamento de distúrbio bipolar ii, compreendendo administrar a um paciente que dele necessite uma quantidade terapeuticamente eficaz de lumateperona, na forma de sal livre ou farmaceuticamente aceitável, opcionalmente na forma deuterada.
BR112022000231A 2019-07-07 2020-07-07 Novos métodos BR112022000231A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962871170P 2019-07-07 2019-07-07
PCT/US2020/041063 WO2021007245A1 (en) 2019-07-07 2020-07-07 Novel methods

Publications (1)

Publication Number Publication Date
BR112022000231A2 true BR112022000231A2 (pt) 2022-02-22

Family

ID=74066254

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000231A BR112022000231A2 (pt) 2019-07-07 2020-07-07 Novos métodos

Country Status (11)

Country Link
US (2) US20210000822A1 (pt)
EP (2) EP3993798A4 (pt)
JP (1) JP2022539821A (pt)
KR (1) KR20220029744A (pt)
CN (1) CN114072150A (pt)
AU (1) AU2020311894A1 (pt)
BR (1) BR112022000231A2 (pt)
CA (1) CA3141223A1 (pt)
IL (1) IL289589A (pt)
MX (1) MX2022000143A (pt)
WO (1) WO2021007245A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021338439A1 (en) * 2020-09-04 2023-02-23 Intra-Cellular Therapies, Inc. Novel salts, crystals, and co-crystals
WO2024030835A2 (en) * 2022-07-30 2024-02-08 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN115671057A (zh) * 2022-10-19 2023-02-03 四川迈可隆生物科技有限公司 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法
CN115554237B (zh) * 2022-12-08 2023-09-12 山东则正医药技术有限公司 一种卢美哌隆原位凝胶长效注射剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
DE60014370T2 (de) 1999-06-15 2006-02-09 Bristol-Myers Squibb Pharma Co., Wilmington Substituierte heterocyclylkondensierte gamma carboline
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
BR112012026881A2 (pt) 2010-04-22 2017-10-10 Intra Cellular Therapies Inc compostos orgânicos
EP2836213B1 (en) 2012-04-14 2018-07-04 Intra-Cellular Therapies, Inc. Fused gamma carbolines
KR20230023817A (ko) * 2013-12-03 2023-02-17 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
RU2020123764A (ru) 2014-04-04 2020-08-05 Интра-Селлулар Терапиз, Инк. Органические соединения
CN106456638A (zh) * 2014-04-04 2017-02-22 细胞内治疗公司 有机化合物
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
WO2018031535A1 (en) * 2016-08-09 2018-02-15 Assia Chemical Industries Ltd. Solid state forms of lumateperone ditosylate salt
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶

Also Published As

Publication number Publication date
EP3993798A4 (en) 2023-04-26
JP2022539821A (ja) 2022-09-13
MX2022000143A (es) 2022-02-17
EP4134101A1 (en) 2023-02-15
AU2020311894A1 (en) 2022-01-27
IL289589A (en) 2022-03-01
US20240066030A1 (en) 2024-02-29
US20210000822A1 (en) 2021-01-07
WO2021007245A1 (en) 2021-01-14
CA3141223A1 (en) 2021-01-14
EP3993798A1 (en) 2022-05-11
KR20220029744A (ko) 2022-03-08
CN114072150A (zh) 2022-02-18

Similar Documents

Publication Publication Date Title
BR112022000231A2 (pt) Novos métodos
BR112017023233A2 (pt) métodos para tratamento de câncer
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
AR101740A1 (es) Terapia de combinación y composiciones
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
BR112014012155A2 (pt) método de tratamento de tumores que são resistentes a terapias de egfr por conjugado de agente citotóxico de anticorpo egfr
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
BR112016029067A2 (pt) ?composto, composição farmacêutica, e, métodos para inibir o canal de potássio medular externo renal, para causar diurese, natriurese ou ambas e para tratar um ou mais distúrbios?
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
EA202193276A1 (ru) Способы лечения холангиокарциномы
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.